Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Post by rovaniemiroveron Sep 05, 2019 1:00pm
194 Views
Post# 30098754

what should have been big news for MBX ...

what should have been big news for MBX ...... today looks like a complete dud, based on market reaction.  McWhirter a couple of months ago on BNN lunch hour show mentioned he's got a $0.70/share target on MBX because they would have a huge opportunity in generating revenues from HPV diagnostic tests.  Today MBX announces that they have approval for their HPV tests for the European market, where they are already selling a lot of other product, and so they have the distribution network all set up already.  This announcement should have lit a fire under the share price and should have confirmed McWhirter's prognostication.  What gives?!
Bullboard Posts